Trial NCT03071094

View at ClinicalTrials.gov 
Org. Study IDs: TG6006.01

Last trial update was posted on 2021-11-19

MeSH Interventions

Nivolumab

MeSH Conditions

Carcinoma Carcinoma, Hepatocellular

Other Conditions

Hepatocellular Carcinoma (HCC)

Stopping Reasons

The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and nivolumab in their respective pivotal trials (i.e., PHOCUS and CheckMate 459).

Limitations And Caveats

The study was terminated prematurely as per Sponsor's decision based on the failure of Pexa-Vec and nivolumab in their respective pivotal trials in HCC. As a consequence, the enrollment in Phase IIa was not completed.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID